|
|
The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.
Addicts to opiates often avoid treatment because they are afraid of withdrawal. Though unpleasant, with proper management, withdrawal is rarely fatal and passes relatively quickly.
The toxic levels for lithium carbonate are close to the therapeutic levels. Signs of toxicity include fine hand tremor, polyuria, mild thirst, nausea, general discomfort, diarrhea, vomiting, drowsiness, muscular weakness, lack of coordination, ataxia, giddiness, tinnitus, and blurred vision.
Persons who overdose with cardiac glycosides have a better chance of overall survival if they can survive the first 24 hours after the overdose.
Computer programs are available that crosscheck a new drug's possible trade name with all other trade names currently available. These programs detect dangerous similarities between names and alert the manufacturer of the drug.
![The approval of a new drug is a four-stage process: (1) preclinical investigation, (2) clinical inve](https://biology-forums.com/gallery/47/medium_246815_06_04_15_9_49_12_21219513.jpeg)
![James A. Garfield lies mortally wounded. After failing to locate the bullet, surgeons called in Alex](https://biology-forums.com/gallery/47/medium_376716_26_08_15_11_16_34_224422432.jpeg)